South Korea · Delayed Price · Currency is KRW Kanaph Therapeutics Company Description
Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States.
The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker therapy for patients with wet age-related macular degeneration and geographic atrophy, which has completed preclinical stage; KNP-502, a dual antagonist of the prostaglandin E2 receptors EP2 and EP4 that is in Phase 1 clinical trials to overcome PGE2-mediated immunosuppression within the tumor microenvironment; KNP-503, a SHP2 allosteric inhibitor, which is in preclinical trials for the treatment of various KRAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma; and KNP-504, a SOS1 inhibitor, which has completed preclinical trials for the treatment of RAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and NF1-mutant solid tumor.
It also discovers KNP-701, an anti-cMET and anti-EGFR bispecific ADC for treating non-small cell lung cancer.
Kanaph Therapeutics Inc. was founded in 2019 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2019 |
| CEO | Byoung Chul Lee |
Contact Details
Address: 3 Itaewon-ro 55-gil Seoul South Korea | |
| Phone | 82 2 798 9438 |
Stock Details
| Ticker Symbol | 0082N0 |
| Exchange | KOSDAQ |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Byoung Chul Lee | Chief Executive Officer |
| Changwon Park | Chief Financial Officer |